Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping.

ABSTRACT: A venous thromboembolism (VTE) with the subsequent risk of pulmonary embolism is a major concern in the treatment of patients with multiple myeloma with thalidomide. The susceptibility to developing a VTE in response to thalidomide therapy is likely to be influenced by both genetic and environmental factors. To test genetic variation associated with treatment related VTE in patient peripheral blood DNA, we used a custom-built molecular inversion probe (MIP)-based single nucleotide polymorphism (SNP) chip containing 3404 SNPs. SNPs on the chip were selected in "functional regions" within 964 genes spanning 67 molecular pathways thought to be involved in the pathogenesis, treatment response, and side effects associated with myeloma therapy. Patients and controls were taken from 3 large clini

SUBMITTER: Johnson DC 

PROVIDER: S-EPMC3601865 | biostudies-literature | 2008 Dec

REPOSITORIES: biostudies-literature